



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: editorialoffice@wjgnet.com

http://www.wjgnet.com

ESPS Peer-review Report

Name of Journal: World Journal of Stem Cells

ESPS Manuscript NO: 7697

Title: Recent Advances in Haplo-Identical Stem Cell Transplantation in Adults with High-Risk Hematological Malignancies

Reviewer code: 00289387

Science editor: Ling-Ling Wen

Date sent for review: 2013-12-09 09:22

Date reviewed: 2014-01-01 23:18

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

In this review paper, Drs. Ricci et al. presented a current clinical trial of allogeneic bone marrow transplant (BMT) for treatment of patients with hematological malignance, most of which lack suitable bone marrow matches or donors. The article substantially illustrated a range of clinical approaches of BMT to advanced hematological diseases including identification of a donor, treatment of graft-verse-host disease and other treatment-related toxicity, and updated several clinical settings and outcomes. This novel regimen significantly minimizes previous side effects such as graft rejection, severe graft-verse-host disease, and prolonged immune suppression, thus potentially holding great promise for the treatment of patients with leukemia. A few concerns need to be addressed. 1) To emphasize the importance of the BMT for patient treatment, it is essential for introducing more background information about the malignant rate of hematological diseases, subtypes of malignant diseases, and how many cases (or rate) of the patients are urgently required for the potential therapy with BMT; otherwise they rapidly succumb to the diseases. 2) Is BMT applicable for treatment of all or some types of leukemia both in children and adults? 3) Growing research evidence and mechanistic studies have established the notion that stem cells or progenitor cells serve as powerful utility for regeneration and function of damaged cells, tissue and/organs. This review lacks mechanistic insight into this new approach, particularly for grafting CD34+ donor progenitor cells and post-transplant administration of G-CSF. In addition, it was not discussed why the donor age is critical for disease outcome, as patients receiving transplants from young donors have more improved disease-free survival and overall survival than those from old donors. 4) A



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: editorialoffice@wjgnet.com

<http://www.wjgnet.com>

few typos should be corrected: “ultimately” should be capital “Ultimately” on p5; after “mortality” on p5 missed a period; the legend of Figure 2 should be corrected. In addition, a full name of HLA on p2 should be provided at the first time rather than it on p3.



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: editorialoffice@wjgnet.com

http://www.wjgnet.com

ESPS Peer-review Report

Name of Journal: World Journal of Stem Cells

ESPS Manuscript NO: 7697

Title: Recent Advances in Haplo-Identical Stem Cell Transplantation in Adults with High-Risk Hematological Malignancies

Reviewer code: 00225340

Science editor: Ling-Ling Wen

Date sent for review: 2013-12-09 09:22

Date reviewed: 2014-01-03 15:15

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

It is an interesting and didactic update on allogeneic bone marrow transplantation. I don't see any particular problems. I would like to have more informations about clinical aspects, above all diagnostic aspects, related to chronic graft-versus-host disease. Moreover, it could be useful to introduce some data on the potential role of stem cell in general and mesencimal stem cell in particular.